+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Conatus Pharmaceuticals - logo

Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Its lead compound, emricasan, is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases. In December 2016, Conatus announced an exclusive option, collaboration and license agreement with Novartis for the global development and commercialization of emricasan. The company was founded in 2005 and is headquartered in San Diego, California.

From
From
Caspases Activators - Pipeline Insight, 2022 - Product Thumbnail Image

Caspases Activators - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
  • Global
From
Portal Hypertension - Pipeline Insight, 2020 - Product Thumbnail Image

Portal Hypertension - Pipeline Insight, 2020

  • Clinical Trials
  • February 2020
  • 106 Pages
  • Global
From
Cirrhosis Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Cirrhosis Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • March 2020
  • 831 Pages
  • Global
From
Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • January 2020
  • 306 Pages
  • Global
From
From
Loading Indicator